Bee product could fight inflammation in kidney patients

NCT ID NCT06438445

Recruiting now Disease control Sponsor: Universidade Federal Fluminense Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking royal jelly supplements can reduce inflammation and slow cell aging in people with chronic kidney disease who are on hemodialysis. Thirty participants will take either royal jelly or a placebo daily for two months. Researchers will measure changes in blood markers related to inflammation and aging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: royal jelly (dietary supplement)
What this could lead to: If it works, this could point toward a simple supplement to reduce inflammation and slow cell aging in kidney disease patients on dialysis.
What could go wrong: This is a very small, early-stage trial with only 30 participants. It tests biomarkers, not direct health outcomes, so even positive results may not translate to real benefits. Royal jelly can cause allergic reactions in some people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMODIALYSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMODIALYSIS KIDNEY FAILURE, CHRONIC OXIDATIVE STRESS

Contacts and locations

Locations

Denise Mafra
RECRUITING

Rio de Janeiro, Rio de Janeiro, 22260050, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.